- Home
- NEOG vs PTGX Comparison
NEOG vs PTGX Comparison
Compare NEOG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOG
- PTGX
- Stock Information
- Founded
- NEOG 1981
- PTGX 2006
- Country
- NEOG United States
- PTGX United States
- Employees
- NEOG N/A
- PTGX N/A
- Industry
- NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NEOG Health Care
- PTGX Health Care
- Exchange
- NEOG Nasdaq
- PTGX Nasdaq
- Market Cap
- NEOG 1.1B
- PTGX 3.3B
- IPO Year
- NEOG 1989
- PTGX 2016
- Fundamental
- Price
- NEOG $4.97
- PTGX $55.32
- Analyst Decision
- NEOG Buy
- PTGX Strong Buy
- Analyst Count
- NEOG 2
- PTGX 9
- Target Price
- NEOG $7.50
- PTGX $67.11
- AVG Volume (30 Days)
- NEOG 6.4M
- PTGX 900.6K
- Earning Date
- NEOG 07-29-2025
- PTGX 08-05-2025
- Dividend Yield
- NEOG N/A
- PTGX N/A
- EPS Growth
- NEOG N/A
- PTGX N/A
- EPS
- NEOG N/A
- PTGX 0.86
- Revenue
- NEOG $905,996,000.00
- PTGX $207,801,000.00
- Revenue This Year
- NEOG N/A
- PTGX N/A
- Revenue Next Year
- NEOG $0.48
- PTGX $53.09
- P/E Ratio
- NEOG N/A
- PTGX $63.65
- Revenue Growth
- NEOG N/A
- PTGX N/A
- 52 Week Low
- NEOG $3.87
- PTGX $32.50
- 52 Week High
- NEOG $18.58
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- NEOG 43.27
- PTGX 61.17
- Support Level
- NEOG $4.94
- PTGX $49.38
- Resistance Level
- NEOG $5.74
- PTGX $51.51
- Average True Range (ATR)
- NEOG 0.30
- PTGX 2.02
- MACD
- NEOG 0.05
- PTGX 0.02
- Stochastic Oscillator
- NEOG 33.04
- PTGX 75.62
About NEOG Neogen Corporation
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.